BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

C:\STNEXP4\QUERIES\10071699.str





chain nodes :
7 8 10 11 13 14 15 19
ring nodes :
1 2 3 4 5 6
chain bonds :
4-7 8-19 10-11 10-13 14-15
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
4-7 8-19 10-11 10-13 14-15
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G1:O,N

G2:[*1],[*2]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:CLASS 10:CLASS
11:CLASS 13:CLASS 14:CLASS 15:CLASS 19:CLASS
Generic attributes :
8:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

Element Count :
Node 8: Limited
C,C1-4

=>
Uploading 10071699.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,N
G2 [@1],[@2]

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam
SAMPLE SEARCH INITIATED 19:01:38 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 10112 TO ITERATE

9.9% PROCESSED 1000 ITERATIONS 1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 196219 TO 208261
PROJECTED ANSWERS: 12 TO 392

L2 1 SEA SSS SAM L1

=> s l1 sss ful
FULL SEARCH INITIATED 19:02:00 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 201366 TO ITERATE

```
100.0% PROCESSED  201366 ITERATIONS                          237 ANSWERS
SEARCH TIME: 00.00.06

L3          237 SEA SSS FUL L1

=> d his

     (FILE 'HOME' ENTERED AT 19:01:06 ON 01 JUL 2003)

     FILE 'REGISTRY' ENTERED AT 19:01:10 ON 01 JUL 2003
L1               STRUCTURE UPLOADED
L2             1 S L1 SSS SAM
L3           237 S L1 SSS FUL

     FILE 'CAPLUS' ENTERED AT 19:02:12 ON 01 JUL 2003

=> s l3
L4           20 L3

=> d l4 1-20 bib,ab,hitstr
```

L4 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2003 ACS
AN 2003:154244 CAPLUS
DN 138:187786
TI Preparation of pyrimidinylthiazoles as antiinflammatories.
IN Love, Christopher John; Van Wauwe, Jean Pierre Frans; De Brabander, Marc J.; Moses, Roger Clive; Goncharenko, Mykhalyo; Cooymans, Ludwig Paul; Vandermaesen, Nele; Diels, Gaston Stanislas Marcella; Sibley, Anthony William; Noula, Caterina
PA Janssen Pharmaceutica N.V., Belg.
SO PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003015776	A1	20030227	WO 2002-EP8956	20020809

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI EP 2001-203088 A 20010813
OS MARPAT 138:187786
AB Use of title compds. [I; Z = halo, alkyl; hydroxyalkyl, carboxyalkyl, cyanoalkyl, aminoalkyl, aminoalkyl, aminocarbonylalkyl, alkoxyalkyl, polyhaloalkyl, alkoxy, cyano, amino, aminocarbonyl, aminocarbonyl, alkyloxycarbonyl, alkylcarbonyloxy, etc.; Q = (substituted) cycloalkyl, furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzothiazolyl, benzoxazolyl, benzimidazolyl, indazolyl, imidazopyridyl, etc.; L = substituted Ph, (substituted) monocyclic 5-6 membered partially satd. or arom. heterocycle, bicyclic partially satd. or arom. heterocycle] for the manuf. of a medicament for the prevention or the treatment of diseases mediated through tumor necrosis factor-alpha (TNF-.alpha.) and/or interleukin-12 (IL-12), is claimed. Thus, Me 3-[4-methyl-2-(4-trifluoromethylphenyl)thiazol-5-yl]-3-oxopropanoate was added to a mixt. prepd. from NaOMe and diguanidine carbonate in EtOCH2CH2OH followed by 3 h reflux to give 76% 5- (2-aminopyrimidin-4-yl)-4-methyl-2-(4-trifluoromethylphenyl)thiazole. The latter at 10-8 M gave 92% inhibition of IL-12p70.
IT **499796-18-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrimidinylthiazoles as antiinflammatories)
RN 499796-18-8 CAPLUS
CN 4-Thiazolecarboxamide, 5-(2-amino-4-pyrimidinyl)-2-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2003 ACS
AN 2002:928744 CAPLUS
DN 138:287622
TI Solid-phase synthesis of 2-(4-carbamoylpyrazolyl)-4-alkylamino-6-aminopyrimidine derivatives
AU Haruta, Makoto; Ejima, Akio; Tanaka, Hiroshi; Takahashi, Takashi
CS Discovery Res. Lab. New Product Res. Lab., Daiichi Pharmaceutical Co. Ltd., 16-13, Kita-Kasai 1-Chome Edogawa-ku, Tokyo, Japan
SO Heterocycles (2002), 58, 79-83
CODEN: HTCYAM; ISSN: 0385-5414
PB Japan Institute of Heterocyclic Chemistry
DT Journal
LA English
OS CASREACT 138:287622

not prior Nov/2002.

AB Solid-phase synthesis of 2-(4-carbamoylpyrazolyl)-4-alkylamino-6-aminopyrimidines, e.g. I, was accomplished via amination/amidation of solid supported phenol derivs. II (R = NHCH2C6H4OH-4). The methodol. allows the construction of a library of 2-(1-pyrazolyl)pyrimidines.

IT **504434-50-8P 504434-52-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(solid-phase synthesis of (carbamoylpyrazolyl)(alkylamino)aminopyrimidine derivs. via amination/amidation)

RN 504434-50-8 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-[6-chloro-2-[[[4-[(2-methoxyethoxy)methoxy]phenyl]methyl]amino]-4-pyrimidinyl]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 504434-52-0 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-[6-chloro-2-[[(4-hydroxyphenyl)methyl]amino]-4-pyrimidinyl]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



IT **256930-33-3P 504434-55-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(solid-phase synthesis of (carbamoylpyrazolyl)(alkylamino)aminopyrimidine derivs. via amination/amidation)

RN 256930-33-3 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-(2-amino-6-chloro-4-pyrimidinyl)-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 504434-55-3 CAPLUS
CN 1H-Pyrazole-4-carboxamide, 1-[2-amino-6-(4-morpholinyl)-4-pyrimidinyl]-5-methyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

VOLUME 138 CODEN: CHABA8 NUMBER 19
ISSN: 0009-2258

CHEMICAL ABSTRACTS®

KEY TO THE WORLD'S CHEMICAL LITERATURE®

A publication of CHEMICAL ABSTRACTS SERVICE *published weekly by*

△ THE AMERICAN CHEMICAL SOCIETY △

(PART 1 of 2 PARTS)

MAY 12, 2003

138: 287621e **Improved cyclization process for synthesis of trimethoprim from 3,4,5-trimethoxybenzaldehyde.** Wang, Lin; Yang, Hao; Chen, Wen-Tao; Xing, Wen-Ru; Yao, Xing-Zhi (Department of Chemistry, Nanyang Teachers College, Nanyang, Peop. Rep. China 473061). *Yingyong Huaxue* **2002**, 19(11), 1072-1075 (Ch), Yingyong Huaxue Bianji Weiyuanhui. Title compd. was prepd. from 3,4,5-trimethoxybenzaldehyde and β-methoxypropionitrile via condensation, forming α-(3,4,5-trimethoxybenzyl)-β-dimethoxypropionitrile, further cyclization with guanidine nitrate, got the product with yield 90%. The cyclization process was carried out by double reflux instead of conventional single reflux, and at the cyclization stage a solvent was added to the reaction mixt.. The cyclization conditions were obtained by orthogonal factors and single factors expts.

138: 287622f **Solid-phase synthesis of 2-(4-carbamoylpyrazolyl)-4-alkylamino-6-aminopyrimidine derivatives.** Haruta, Makoto; Ejima, Akio; Tanaka, Hiroshi; Takahashi, Takashi (Discovery Res. Lab. New Product Res. Lab., Daiichi Pharmaceutical Co. Ltd., 16-13, Kita-Kasai 1-Chome Edogawa-ku, Tokyo, Japan). *Heterocycles* **2002**, 58, 79-83 (Eng), Japan Institute of Heterocyclic Chemistry. Solid-phase synthesis of 2-(4-carbamoylpyrazolyl)-4-alkylamino-6-



I



II

aminopyrimidines, e.g. **I**, was accomplished via amination/amidation of solid supported phenol derivs. **II** (R = $NHCH_2C_6H_4OH$-4). The methodol. allows the construction of a library of 2-(1-pyrazolyl)pyrimidines.

138: 287623g **Asymmetric synthesis of 4,6-disubstituted 1,2,3,4,5,6-hexahydro-5-hydroxypyrimidin-2-ones as potential HIV-protease-inhibitors.** Enders, Dieter; Wortmann, Lars (Inst. Organische Chemie, RWTH Aachen, 52074 Aachen, Germany). *Heterocycles* **2002**, 58, 293-299 (Eng), Japan Institute of Heterocyclic Chemistry. Hydroxy-substituted hexahydropyrimidinones **I** (R^1 = R^2 =



I



III

Me_2CH, Bu, $PhCH_2$, $PhCH_2CH_2$; R^1 = $PhCH_2CH_2$, R^2 = $PhCH_2$), potential HIV protease inhibitors, were enantioselectively prepd. in five steps starting from readily available 1,3-dibenzyl-2,5-tetrahydropyrimidinedione (**II**). The key step of the synthesis is the auxiliary directed stereoselective alkylation of hydrazone **III**, prepd. from **II** and (S)-1-amino-2-methoxymethylpyrrolidine (SAMP).

138: 287624h **Preparation of the derivatives of 5-arylidenebabituric acid by grinding method.** Geng, Li-Jun; Wang, Shu-Xiang; Li, Ji-Tai; Liu, Chun-Hong (College Chem. Environmental Sci., Hebei Univ., Boading, Peop. Rep. China 071002). *Youji Huaxue* **2002**, 22(12), 1047-1049 (Ch), Kexue Chubanshe. Grinding a mixt. of benzaldehydes, barbituric acid and $ZnCl_2$ at room temp. (without any solvents) gave 5-arylidenebabituric acid in high yields, providing a simple and efficient route to these compds.

138: 287625j **[1,2,4]Triazolo[1,5-c]quinazolin-2(3H)-ones and their thio analogues: a one pot synthesis.** Rajan, K. Subramanian; Raghu Ram Rao, A.; Mogilaiah, K.; Prasad, M. Raghu (Medicinal Chemistry Division, University College of Pharmaceutical Sciences, Kakatiya University, Warangal, 506 009 India). *Journal of Chemical Research, Synopses* **2002**, (10), 490-492 (Eng), Science Reviews. A facile



I

synthetic route for 5-aryl[1,2,4]triazolo[1,5-c]quinazolin-2(3H)-ones and 2(3H)-thiones **I** (X = O, S, Ar = Ph, 4-MeC_6H_4, 2-$MeOC_6H_4$, 3-$MeOC_6H_4$, 4-$MeOC_6H_4$, 4-BrC_6H_4, 4-$O_2NC_6H_4$) has been developed. Cyclization of 3,1-benzoxazin-4(3H)-ones with semicarbazide or semithiocarbazide gave **I** in good yields under anhyd. conditions. This work is part of an effort to develop new bronchodilators for the treatment of asthma.

138: 287626k **Attachment of Unreactive Amines to the Solid Support: Synthesis of Phenyl-Substituted Anilines, 2-Aminopyridines, and 2-Aminopyrimidines.** Zhu, Shirong; Shi, Shuhao; Gerritz, Samuel W.; Sofia, Michael J. (Bristol-Myers Squibb, Wallingford, CT 06492 USA). *Journal of Combinatorial Chemistry* **2003**, 5(3), 205-207 (Eng), American Chemical Society. An efficient method to attach unreactive amines, e.g., anilines, aminopyridines and aminopyrimidines, to Wang resin via the carbamate linker has been developed. Increasing the reactivity of the haloarylamines by deprotonation with sodium bis(trimethylsilyl)amide was key to successfully attaching the amine to the resin. To exemplify the utility of this approach, a small library of phenyl-substituted aryl- and heteroaryl amines was synthesized via Suzuki coupling of the immobilized haloarylamine with a range of phenylboronic acids.

138: 287627m **Suzuki Cross-Coupling of Solid-Supported Chloropyrimidines with Arylboronic Acids.** Wade, Janice V.; Krueger, Clinton A. (ChemRx Division, Discovery Partners International Inc., South San Francisco, CA 94080 USA). *Journal of Combinatorial Chemistry* **2003**, 5(3), 267-272 (Eng), American Chemical Society. The util-



I

ity of the Suzuki cross-coupling to synthesize biaryl compds. is expanded herein to include reactions of resin-supported chloropyrimidines with boronic acids. In particular, an efficient method is described for the synthesis of a library of biaryl compds. from solid-supported chloropyrimidines. The Suzuki reaction was performed in an inert atm. using $Pd_2(dba)_3/P(t\text{-}Bu)_3$ as catalyst, spray-dried KF as base, and THF as solvent. The reaction was allowed to proceed overnight at 50 °C. Upon cleavage with acid, a library of 4-(substituted amino)-6-arylpyrimidines, e.g. **I**, was obtained in moderate yield and high purity.

138: 287628n **Solution- and Solid-Phase Parallel Synthesis of 4-Alkoxy-Substituted Pyrimidines with High Molecular Diversity.** Font, David; Heras, Montserrat; Villalgordo, Jose M. (Departament de Quimica Facultat de Ciencies, Universitat de Girona, Girona, Spain E-17071). *Journal of Combinatorial Chemistry* **2003**, 5(3), 311-321 (Eng), American Chemical Society. A simple and straightforward methodol. toward the synthesis of novel 2,6-disubstituted-4-alkoxypyrimidine derivs. has been developed. This methodol., initially developed in soln., can be perfectly adapted to the solid support under analogous conditions, taking full advantage of automated parallel synthesis systems. This successful methodol. benefits from the key role played by the thioether linkage placed at the 2-position in a double manner: on one side, the steric effect exerted by the thioether linkage is likely to be responsible for the very high obsd. selectivity toward the formation of the O-alkylation products. On the other side, this sulfur linkage can serve not only as a robust point of attachment for the heterocycle, stable to a no. of reaction conditions, but also as a means of introducing a new element of diversity through activation to the sulfone (safety-catch linker concept) and subsequent ipso-substitution reaction with a variety of different N-nucleophiles.

138: 287629p **Studies on Quinazolines. 11.Intramolecular Imidate-Amide Rearrangement of 2-Substituted 4-(ω-Chloroalkoxy)quinazoline Derivatives. 1,3 -O → N Shift of Chloroalkyl Groups via Cyclic 1,3-Azaoxonium Intermediates.** Chen, Grace Shiahuy; Kalchar, Shivaramayya; Kuo, Chun-Wei; Chang, Chih-Shiang; Usifoh, Cyril O.; Cherri, Ji-Wang (School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Peop. Rep. China 100). *Journal of Organic Chemistry* **2003**, 68(6), 2502-2505 (Eng), American Chemical Society. The ω-chloroalkylation of 2-substituted quinazolin-4(3H)-



I



II



III

one derivs. **I** (R = PH, Bn) with Br-$(CH_2)_n$-Cl (n = 2-4) and the intramol. imidate-amide rearrangement of the alkylated products are described. At room temp., the 2-Ph substituent promoted O-alkylation, whereas the less steric 2-benzyl group led to a higher ratio of

L4 ANSWER 3 OF 20 CAPLUS COPYRIGHT 2003 ACS
AN 2002:849620 CAPLUS
DN 137:353031
TI Preparation of 4-aryltriazoles useful in treating diseases associated with unwanted cytokine activity
IN Tullis, Joshua Spector; Van Rens, John Charles; Clark, Michael Philip; Blass, Benjamin Eric; Natchus, Michael George; De, Biswanath
PA The Procter & Gamble Company, USA
SO PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002088113	A1	20021107	WO 2002-US13075	20020425
W:	AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003100558	A1	20030529	US 2002-132981	20020424
PRAI US 2001-287604P	P	20010430		

OS MARPAT 137:353031
AB The present invention relates to 4-aryltriazoles (shown as I; e.g. 4-(4-Fluorophenyl)-5-[2-[(phenylmethyl)amino]pyrimidin-4-yl]-1-ethoxymethyl-1,2,3-triazole) wherein R1 is independently: lower alkyl, lower alkenyl, lower alkynyl, lower heteroalkyl, lower heteroalkenyl, lower heteroalkynyl, heterocycloalkyl, heteroaryl, halo, CN, OR4, SR4, S(O)R4, S(O)2R4, and NR4R5; Q is II or III, and other variables are defined in the claims. Said compds. are useful in treating diseases assocd. with unwanted cytokine activity, inter alia, interleukin-1 (IL-1) and tumor necrosis factor (TNF) from cells, e.g. osteoarthritis, rheumatoid arthritis, and congestive heart failure (no data). Although the methods of prepn. are not claimed, several example prepns. are included and about 70 specific claimed compds. are listed.
IT **474557-12-5P**, 4-(4-Fluorophenyl)-5-[2-((R)-1-phenylethylamino)pyrimidin-4-yl]-1-ethoxycarbonyl-1,2,3-triazole **474557-14-7P 474557-15-8P**, 4-(4-Fluorophenyl)-5-[2-((R)-1-phenylethylamino)pyrimidin-4-yl]-1-(2-methoxyethoxycarbonyl)-1,2,3-triazole **474557-25-0P**, 4-(4-Fluorophenyl)-5-[2-((R)-1-phenylethylamino)pyrimidin-4-yl]-1-(N-ethyl-N-phenylaminocarbonyl)-1,2,3-triazole **474557-27-2P**, 4-(4-Fluorophenyl)-5-[2-((R)-1-phenylethylamino)pyrimidin-4-yl]-1-(N,N-dimethylaminocarbonyl)-1,2,3-triazole
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of aryltriazoles useful in treating diseases assocd. with unwanted cytokine activity)
RN 474557-12-5 CAPLUS
CN 1H-1,2,3-Triazole-1-carboxylic acid, 4-(4-fluorophenyl)-5-[2-[[(1R)-1-phenylethyl]amino]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474557-14-7 CAPLUS
CN 1H-1,2,3-Triazole-1-carboxylic acid, 4-(4-fluorophenyl)-5-[2-[[(1R)-1-phenylethyl]amino]-4-pyrimidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474557-15-8 CAPLUS
CN 1H-1,2,3-Triazole-1-carboxylic acid, 4-(4-fluorophenyl)-5-[2-[[(1R)-1-phenylethyl]amino]-4-pyrimidinyl]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474557-25-0 CAPLUS
CN 1H-1,2,3-Triazole-1-carboxamide, N-ethyl-4-(4-fluorophenyl)-N-phenyl-5-[2-[[(1R)-1-phenylethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474557-27-2 CAPLUS
CN 1H-1,2,3-Triazole-1-carboxamide, 4-(4-fluorophenyl)-N,N-dimethyl-5-[2-[[(1R)-1-phenylethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2003 ACS
AN 2002:814126 CAPLUS
DN 137:325327
TI Preparation of thienyl-substituted pyrimidinyl, pyridinyl and triazinyl amines as inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
IN Cao, Jingrong; Green, Jeremy; Moon, Young-Choon; Wang, Jian; Ledeboer, Mark; Harrington, Edmund; Gao, Huai
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 137 pp.
CODEN: PIXXD2
DT Patent
LA English

Common Inventors Not 102(e)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002083667	A2	20021024	WO 2002-US11570	20020410
	WO 2002083667	A3	20030103		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003096816	A1	20030522	US 2002-121035	20020410
PRAI	US 2001-283621P	P	20010413		
	US 2001-292974P	P	20010523		
	US 2001-329440P	P	20011015		

OS MARPAT 137:325327
AB The present invention provides thienyl-substituted pyrimidinyl, pyridinyl and triazinyl amines (shown as I, e.g. 2-methylsulfanyl-5-(2-phenylaminopyrimidin-4-yl)-4-(4-chlorophenyl)thiophene-3-carbonitrile): or a pharmaceutically acceptable deriv. thereof, wherein A, B, Ra, R1, R2, R3 and R4 are as described in the specification. These compds. are inhibitors of protein kinase, particularly inhibitors of JNK, a mammalian protein kinase involved in cell proliferation, cell death and response to extracellular stimuli; Lck and Src kinase. The invention also provides pharmaceutical compns. comprising the inhibitors of the invention and methods of using those compns. in the treatment and prevention of various disorders. Although the methods of prepn. are not claimed, 42 example prepns. of intermediates and I are included. Results of JNK, Src and Lck inhibition are tabulated for many I.
IT **473531-16-7P**, 2-((Ethylamino)carbonyl)-3-(trifluoromethyl)-4-(pyridin-3-yl)-5-(2-(benzylamino)pyrimidin-4-yl)thiophene **473531-17-8P 473531-18-9P**, 2-(Nitromethyl)-3-((ethylamino)carbonyl)-4-((4-chlorophenyl)amino)-5-(2-aminopyrimidin-4-yl)thiophene **473531-32-7P**, 2-(Methylamino)-3-((methylamino)carbonyl)-4-phenyl-5-(2-aminopyrimidin-4-yl)thiophene **473531-33-8P**, 2-(Methylthio)-3-((methylamino)carbonyl)-4-phenyl-5-(2-(phenylamino)pyrimidin-4-yl)thiophene **473531-34-9P**, 2-Ethoxy-3-((methylamino)carbonyl)-4-(4-chlorophenyl)-5-(2-(phenylamino)pyrimidin-4-yl)thiophene **473531-71-4P**, 2-(Methylthio)-3-(ethoxycarbonyl)-4-phenyl-5-(2-((3-hydroxyphenyl)amino)pyrimidin-4-yl)thiophene **473531-72-5P**,

2-(Methylthio)-3-(ethoxycarbonyl)-4-phenyl-5-(2-(phenylamino)pyrimidin-4-yl)thiophene
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of thienyl-substituted pyrimidinyl, pyridinyl and triazinyl amines as inhibitors of JNK and other protein kinases)

RN 473531-16-7 CAPLUS
CN 2-Thiophenecarboxamide, N-ethyl-5-[2-[(phenylmethyl)amino]-4-pyrimidinyl]-4-(3-pyridinyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 473531-17-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[2-(benzoylamino)-4-pyrimidinyl]-4-(ethylamino)-N-(phenylmethyl)-5-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)



RN 473531-18-9 CAPLUS
CN 3-Thiophenecarboxamide, 5-(2-amino-4-pyrimidinyl)-4-[(4-chlorophenyl)amino]-N-ethyl-2-(nitromethyl)- (9CI) (CA INDEX NAME)



RN 473531-32-7 CAPLUS
CN 3-Thiophenecarboxamide, 5-(2-amino-4-pyrimidinyl)-N-methyl-2-(methylamino)-4-phenyl- (9CI) (CA INDEX NAME)



RN 473531-33-8 CAPLUS
CN 3-Thiophenecarboxamide, N-methyl-2-(methylthio)-4-phenyl-5-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 473531-34-9 CAPLUS
CN 3-Thiophenecarboxamide, 4-(4-chlorophenyl)-2-ethoxy-N-methyl-5-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 473531-71-4 CAPLUS
CN 3-Thiophenecarboxylic acid, 5-[2-[(3-hydroxyphenyl)amino]-4-pyrimidinyl]-2-(methylthio)-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 473531-72-5 CAPLUS
CN 3-Thiophenecarboxylic acid, 2-(methylthio)-4-phenyl-5-[2-(phenylamino)-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2003 ACS
AN 2002:777930 CAPLUS
DN 137:294968
TI Preparation of 4-(1H-pyrrolyl)pyrimidin-2-ylamines as inhibitors of cyclin dependent kinases for treating cancer
IN Fischer, Peter Martin; Wang, Shudong; Wood, Gavin
PA Cyclacel Limited, UK
SO PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002079193	A1	20021010	WO 2002-GB1445	20020326
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	GB 2375534	A1	20021120	GB 2002-7229	20020327
PRAI	GB 2001-7901	A	20010329		

OS MARPAT 137:294968
AB The title compds. [I; one of X1 and X2 = NR10 and the other of X1 and X2 = CR9; Z = NH, NHCO, NHSO2, etc.; R1-R3, R9, R10 = H, alkyl, aryl, etc.; R4-R8 = H, alkyl, halo, etc.; with the proviso], useful as inhibitors of cyclin-dependent kinases (CDKs) and hence useful in the treatment of proliferation disorders such as cancer, leukemia, psoriasis and the like, were prepd. Thus, heating 3-dimethylamino-1-(2,4-dimethyl-1H-pyrrol-3-yl)propenone (prepn. given) with 4-fluorophenyl guanidine nitrate in the presence of NaOH in 2-methoxyethanol at 100-120.degree.C under N2 for 6 h afforded 62% II which showed IC50 of 1.0.+-.0.7 .mu.M against CDK2/cyclin E.
IT **467470-28-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of 4-(1H-pyrrolyl)pyrimidin-2-ylamines as inhibitors of cyclin dependent kinases for treating cancer)
RN 467470-28-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2003 ACS
AN 2002:767293 CAPLUS
DN 138:331295
TI Synthesis and mechanism of action of novel pyrimidinyl pyrazole derivatives possessing antiproliferative activity
AU Ohki, Hitoshi; Hirotani, Kenji; Naito, Hiroyuki; Ohsuki, Satoru; Minami, Megumi; Ejima, Akio; Koiso, Yukiko; Hashimoto, Yuichi
CS Medicinal Chemistry Research Laboratory, Daiichi Pharmaceutical Co. Ltd., Edogawa-ku, Tokyo, 134, Japan
SO Bioorganic & Medicinal Chemistry Letters (2002), 12(21), 3191-3193
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
AB Pyrimidinyl pyrazole derivs., prepd. as a new scaffold of an anti-tumor agent, showed antiproliferative activity against human lung cancer cell lines and inhibited tubulin polymn. Furthermore, it was found that compd. I bound at the colchicine site on tubulin, but the tubulin binding pattern was different from that of colchicine. Here, we describe the synthesis of the derivs. and the differences of the action mechanism on tubulin polymn. inhibition between compd. I and colchicine.
IT **210992-71-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and tubulin polymn. inhibition of novel pyrimidinyl pyrazole derivs. possessing antiproliferative activity)
RN 210992-71-5 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-[2-[[(4-methoxyphenyl)methyl]amino]-4-pyrimidinyl]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2003 ACS
AN 2002:637673 CAPLUS
DN 137:185518
TI Pyrimidine derivatives as ERK2 inhibitors
IN Cao, Jingrong; Green, Jeremy; Hale, Michael; Maltais, Francois; Straub, Judy; Tang, Qing; Aronov, Alex
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 188 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002064586	A2	20020822	WO 2002-US3791	20020208
	WO 2002064586	A3	20030206		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003092714	A1	20030515	US 2002-71699	20020208
PRAI	US 2001-267818P	P	20010209		
	US 2001-328768P	P	20011012		

OS MARPAT 137:185518
AB Pyrimidnes I [Z1, Z2 = N, CH; X = 5-membered heteroarom. ring to which QR2 is attached in the 3-position relative to the pyrimidine ring attachment; T, Q = linker group; U = NR4, NR4CO, NR4CONR4, NR4CO2, O, CONR4, CO, CO2, O2C, NR4SO2, SO2NR4, NR4SO2NR4, SO2; m, n = 0, 1; R1 = CN, halogen, NR42, (un)substituted OH; R2 = (un)substituted alkyl, NH2; R3 = H, (un)substituted alkyl, CN; R4 = H, (un)substituted alkyl; NR42 = heterocyclic] were prepd. for use as inhibitors of ERK2 and for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, diabetes, and cardiovascular disease. Thus, the pyrimidine II was obtained by cyclizing the 3-dimethylamino-2-methylacryloylpyrrole fragment with (S)-HOCH2CHPhNHC(:NH)NH2. II had ki <0.1 .mu.M for inhibition of ERK2 in vitro.
IT **449731-36-6P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of pyrimidine derivs. as ERK2 inhibitors)
RN 449731-36-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **449730-24-9P 449730-37-4P 449730-39-6P**
449730-40-9P 449730-49-8P 449730-53-4P
449730-56-7P 449730-60-3P 449730-62-5P
449730-81-8P 449731-00-4P 449731-19-5P
449731-20-8P 449731-21-9P 449731-22-0P
449731-23-1P 449731-24-2P 449731-26-4P
449731-30-0P 449731-31-1P 449731-33-3P
449731-35-5P 449731-39-9P 449731-40-2P
449731-41-3P 449731-43-5P 449731-44-6P
449731-50-4P 449731-51-5P 449731-52-6P
449731-53-7P 449731-54-8P 449731-56-0P
449731-57-1P 449731-58-2P 449731-59-3P
449731-60-6P 449731-62-8P 449731-63-9P
449731-64-0P 449731-65-1P 449731-66-2P
449731-67-3P 449731-68-4P 449731-69-5P
449731-70-8P 449731-71-9P 449731-72-0P
449731-73-1P 449731-74-2P 449731-75-3P
449731-76-4P 449731-77-5P 449731-78-6P
449731-79-7P 449731-80-0P 449731-81-1P
449731-83-3P 449731-85-5P 449731-86-6P
449731-87-7P 449731-88-8P 449731-89-9P
449731-90-2P 449731-91-3P 449731-92-4P
449731-93-5P 449731-94-6P 449731-95-7P
449731-96-8P 449731-97-9P 449731-98-0P
449732-01-8P 449732-05-2P 449732-06-3P
449732-07-4P 449732-08-5P 449732-10-9P
449732-12-1P 449732-13-2P 449732-14-3P
449732-15-4P 449732-16-5P 449732-17-6P
449732-18-7P 449732-19-8P 449732-20-1P
449732-21-2P 449732-22-3P 449732-23-4P
449732-24-5P 449732-25-6P 449732-26-7P
449732-27-8P 449732-28-9P 449732-29-0P
449732-30-3P 449732-31-4P 449732-32-5P
449732-33-6P 449732-34-7P 449732-35-8P
449732-36-9P 449732-37-0P 449732-38-1P
449732-39-2P 449732-40-5P 449732-41-6P
449732-42-7P 449732-43-8P 449732-44-9P
449732-45-0P 449732-46-1P 449732-47-2P
449732-48-3P 449732-49-4P 449732-50-7P
449732-51-8P 449732-52-9P 449732-53-0P
449732-54-1P 449732-55-2P 449732-56-3P
449732-57-4P 449733-07-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrimidine derivs. as ERK2 inhibitors)

RN 449730-24-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-phenyl-4-pyrimidinyl)-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449730-37-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-(3,4-dimethoxyphenyl)-4-pyrimidinyl]-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449730-39-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-(3-methylphenyl)-4-pyrimidinyl]-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449730-40-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-(3-chlorophenyl)-4-pyrimidinyl]-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449730-49-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-phenyl-4-pyrimidinyl)-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449730-53-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-(3,4-dimethoxyphenyl)-4-pyrimidinyl]-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449730-56-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-(3-methylphenyl)-4-pyrimidinyl]-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449730-60-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-(3-chlorophenyl)-4-pyrimidinyl]-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449730-62-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-(3-chloro-2-fluorophenyl)-4-pyrimidinyl]-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449730-81-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-(3-chloro-2-fluorophenyl)-4-pyrimidinyl]-N-[(1R,2R)-2-hydroxy-1-methyl-2-phenylethyl]-N-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 449731-00-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-methyl-4-pyrimidinyl)-N-[[(2S)-tetrahydro-2-furanyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-19-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-(3,5-dichlorophenyl)-4-pyrimidinyl]-N-(1,3-benzodioxol-5-ylmethyl)- (9CI) (CA INDEX NAME)



RN 449731-20-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-(3,5-dichlorophenyl)-4-pyrimidinyl]-N-[2-(dimethylamino)-2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449731-21-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-(3,5-dichlorophenyl)-4-pyrimidinyl]-N-[[4-(methylsulfonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 449731-22-0 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-(1,3-benzodioxol-5-ylmethyl)-4-[5-(3,5-dichlorophenyl)-2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 449731-23-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[5-(3,5-dichlorophenyl)-2-(phenylamino)-4-pyrimidinyl]-N-[2-(4-morpholinyl)-2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449731-24-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-[3-fluoro-5-(trifluoromethyl)phenyl]-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-26-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-methyl-4-pyrimidinyl)-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449731-30-0 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[5-methyl-2-(phenylamino)-4-pyrimidinyl]-N-propyl- (9CI) (CA INDEX NAME)



RN 449731-31-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[5-methyl-2-(phenylamino)-4-pyrimidinyl]-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 449731-33-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-cyclopropyl-4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 449731-35-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-39-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-(2-aminoethyl)-4-[5-methyl-2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 449731-40-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-4-pyrimidinyl)-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449731-41-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-4-pyrimidinyl)-N-[(1R,2R)-2-hydroxy-1-methyl-2-phenylethyl]-N-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 449731-43-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 449731-44-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-ethyl-4-pyrimidinyl)-N-[2-(6-methoxy-1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 449731-50-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[[2-(diethylamino)ethyl]amino]-5-methyl-4-pyrimidinyl]-N-[(3,4-difluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449731-51-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[5-methyl-2-[[2-(1-piperidinyl)-4-quinazolinyl]amino]-4-pyrimidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 449731-52-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl]-4-[5-methyl-2-(methylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 449731-53-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl]-4-[5-methyl-2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 449731-54-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(3-fluorophenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-56-0 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(3-hydroxyphenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-57-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(1,3-benzodioxol-5-ylamino)-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-58-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[[4-(aminosulfonyl)phenyl]amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-59-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[[3-(phenylmethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-60-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(trans-4-hydroxycyclohexyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-62-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[5-cyclopropyl-2-(phenylamino)-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-63-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[1-(3-fluoro-4-methylphenyl)-2-hydroxyethyl]-4-[5-methyl-2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 449731-64-0 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[2-hydroxy-1-[3-(trifluoromethyl)phenyl]ethyl]-4-[5-methyl-2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 449731-65-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[1-(3-fluoro-4-methylphenyl)-2-hydroxyethyl]-4-[2-[(3-fluorophenyl)amino]-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 449731-66-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(3-fluorophenyl)amino]-5-methyl-4-pyrimidinyl]-N-[2-hydroxy-1-[3-(trifluoromethyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 449731-67-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[[3-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-68-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[(phenylmethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-69-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(3,4-dimethylphenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-70-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[[4-(phenylmethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-71-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[(1-methylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-72-0 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[(2,2,2-trifluoroethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-73-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[2-[[(1S)-2-hydroxy-1-phenylethyl]amino]-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-74-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[2-[(2-methoxyphenyl)amino]-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-75-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-76-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[(2-methylpropyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-77-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(cyclopropylmethyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-78-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-(methoxymethyl)-2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-79-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-(methoxymethyl)-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-80-0 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(cyclopropylamino)-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-81-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-(propylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-83-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[2-[[(1R)-2-hydroxy-1-phenylethyl]amino]-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-85-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 449731-86-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-(2-hydroxy-2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 449731-87-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-[(1S,2S)-2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-88-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-89-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-[(1R)-3-hydroxy-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-90-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-[(1S)-3-hydroxy-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-91-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[[1-(hydroxymethyl)cyclopropyl]amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-92-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2-hydroxyethyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-93-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[[(1R)-2-hydroxy-1-methylethyl]amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-94-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[2-[[(2R)-2-hydroxypropyl]amino]-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-95-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[2-[[(2S)-2-hydroxypropyl]amino]-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-96-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2-hydroxycyclohexyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-97-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-4-pyrimidinyl)-N-[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 449731-98-0 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-4-pyrimidinyl)-N-[(1R)-2-hydroxy-1-methyl-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-01-8 CAPLUS
CN Benzeneacetic acid, .alpha.-[[[4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]amino]-, methyl ester, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-05-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-[2-hydroxy-1-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449732-06-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-(hydroxymethyl)-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-07-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-[1-[3-fluoro-5-(trifluoromethyl)phenyl]-2-hydroxyethyl]- (9CI) (CA INDEX NAME)



RN 449732-08-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-[1-(3-fluorophenyl)-2-hydroxyethyl]- (9CI) (CA INDEX NAME)



RN 449732-10-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-[1-(2-fluorophenyl)-2-hydroxyethyl]- (9CI) (CA INDEX NAME)





RN 449732-12-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[[2-cyclopropyl-1-(hydroxymethyl)ethyl]amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-13-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2,3-dimethylphenyl)amino]-5-methyl-4-

pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-14-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethoxyamino)-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-15-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[[(1S)-1-(hydroxymethyl)-2-methylpropyl]amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-16-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-(2-oxo-1-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 449732-17-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-[3-(trifluoromethyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-18-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(3-fluorophenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-[3-(trifluoromethyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-19-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2-chlorophenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-[3-(trifluoromethyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-20-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[[(1S)-2-hydroxy-1-phenylethyl]amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-[3-(trifluoromethyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-21-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(cyclopropylamino)-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-[3-(trifluoromethyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-22-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(cyclopropylamino)-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-(2-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-23-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[2-(cyclopropylamino)-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-24-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(cyclopropylamino)-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-25-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[2-(methoxyamino)-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-26-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[(1-methylethoxy)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-27-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[[3-(dimethylamino)phenyl]amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-28-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]-4-[2-[(2-hydroxyphenyl)amino]-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-29-0 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]-4-[2-[[[[(1S)-2-hydroxy-1-phenylethyl]amino]carbonyl]amino]-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-30-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2,3-dimethylphenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-31-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(3-fluorophenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-32-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(acetylamino)-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-33-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[(2-methylphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-34-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-(3-pyridinylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-35-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[[[(2S)-tetrahydro-2-furanyl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-36-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[[[(2R)-tetrahydro-2-furanyl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-37-0 CAPLUS
CN Hydrazinecarboxylic acid, 2-[4-[5-[[[(1S)-2-hydroxy-1-phenylethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-38-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[(3-pyridinylmethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-39-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(cyclopropylmethoxy)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-40-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[2-(3-isoxazolylamino)-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 449732-41-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[[(1S)-2-hydroxy-1-methylethyl]amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-42-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]-4-[5-methyl-2-[(2-methylphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-43-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-methyl-2-[(2-methylphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-44-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2-hydroxyethoxy)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-45-0 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(2,2-dimethylhydrazino)-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-46-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[[2-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-47-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-(4-morpholinylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-48-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[(5-methyl-3-isoxazolyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 449732-49-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[[(1S)-1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl]amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-50-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-fluorophenyl)-2-hydroxyethyl]-4-[5-methyl-2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-51-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[2-[[(1S)-1-(hydroxymethyl)propyl]amino]-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-52-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[2-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-53-0 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]-4-[2-[[(1S)-1-(hydroxymethyl)propyl]amino]-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-54-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-55-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[[(1S)-1-(hydroxymethyl)propyl]amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-56-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[(2-methylcyclopropyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-57-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(cyanoamino)-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449733-07-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-(3-chlorophenyl)-4-pyrimidinyl]-N-methyl-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



IT **338403-73-9P 449730-92-1P 449730-93-2P**
449730-94-3P 449730-95-4P 449730-96-5P
449730-97-6P 449730-98-7P 449730-99-8P
449731-01-5P 449731-02-6P 449731-03-7P
449731-04-8P 449731-05-9P 449731-06-0P
449731-07-1P 449731-08-2P 449731-09-3P
449731-10-6P 449731-11-7P 449731-12-8P
449731-13-9P 449731-14-0P 449731-15-1P
449731-16-2P 449731-17-3P 449731-18-4P
449731-25-3P 449731-27-5P 449731-28-6P
449731-29-7P 449731-32-2P 449731-34-4P
449731-37-7P 449731-38-8P 449731-45-7P
449731-46-8P 449731-47-9P 449731-48-0P
449731-49-1P 449731-55-9P 449731-61-7P
449731-82-2P 449731-84-4P 449731-99-1P
449732-00-7P 449732-02-9P 449732-03-0P
449732-04-1P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrimidine derivs. as ERK2 inhibitors)

RN 338403-73-9 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-phenyl-4-pyrimidinyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 449730-92-1 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-methyl-4-pyrimidinyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449730-93-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-methyl-4-pyrimidinyl)-N-[(3,4-difluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449730-94-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-methyl-4-pyrimidinyl)-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449730-95-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-methyl-4-pyrimidinyl)-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449730-96-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-methyl-4-pyrimidinyl)-N-[(3-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449730-97-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-methyl-4-pyrimidinyl)-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449730-98-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-methyl-4-pyrimidinyl)-N-[(3-chloro-4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449730-99-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-methyl-4-pyrimidinyl)-N-[[(2R)-tetrahydro-2-furanyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-01-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-methyl-4-pyrimidinyl)-N-[(1R)-3-hydroxy-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-02-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-methyl-4-pyrimidinyl)-N-[(1S)-3-hydroxy-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-03-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(3-chloro-4-fluorophenyl)methyl]-4-(2,5-diamino-4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 449731-04-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-(methylamino)-4-pyrimidinyl]-N-[(3-chloro-4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449731-05-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[5-(acetylamino)-2-amino-4-pyrimidinyl]-N-[(3-chloro-4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449731-06-0 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-[[(methylamino)carbonyl]amino]-4-pyrimidinyl]-N-[(3-chloro-4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449731-07-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-hydroxy-4-pyrimidinyl)-N-[(3-chloro-4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449731-08-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-[(methylamino)methyl]-4-pyrimidinyl]-N-[(3-chloro-4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449731-09-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-(hydroxymethyl)-4-pyrimidinyl]-N-[(3-chloro-4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449731-10-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(3-chloro-4-fluorophenyl)methyl]-4-[2-(cyclohexylamino)-5-[[(methylamino)carbonyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 449731-11-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(acetylamino)-5-[[(methylamino)carbonyl]amino]-4-pyrimidinyl]-N-[(3-chloro-4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449731-12-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(3-chloro-4-fluorophenyl)methyl]-4-[5-hydroxy-2-[(methylsulfonyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 449731-13-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-(methylsulfonyl)-4-pyrimidinyl]-N-[(3-chloro-4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449731-14-0 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-(hydroxymethyl)-4-pyrimidinyl]-N-[(3,4-difluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449731-15-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(cyclohexylamino)-5-methyl-4-pyrimidinyl]-N-[(3,4-difluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449731-16-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-(3,5-dichlorophenyl)-4-pyrimidinyl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 449731-17-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[5-(3,5-dichlorophenyl)-2-(phenylamino)-4-pyrimidinyl]-N-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 449731-18-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-(3,5-dichlorophenyl)-4-pyrimidinyl]-N-[(1R)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-25-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-propyl-4-pyrimidinyl)-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449731-27-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[5-methyl-2-(methylamino)-4-pyrimidinyl]-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449731-28-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(methylamino)-4-pyrimidinyl]-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449731-29-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[2-(dimethylamino)ethyl]-4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 449731-32-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-(1-naphthalenylmethyl)- (9CI) (CA INDEX NAME)



RN 449731-34-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-4-pyrimidinyl]-N-[[2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 449731-37-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-4-pyrimidinyl]-N-(4-methylcyclohexyl)- (9CI) (CA INDEX NAME)



RN 449731-38-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[5-ethyl-2-(phenylamino)-4-pyrimidinyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 449731-45-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[5-methyl-2-(phenylamino)-4-pyrimidinyl]-N-(2-phenoxyethyl)- (9CI) (CA INDEX NAME)



RN 449731-46-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[5-methyl-2-(phenylamino)-4-pyrimidinyl]-N-(1-methyl-3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 449731-47-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-(1H-benzimidazol-2-ylmethyl)-4-[5-methyl-2-(methylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 449731-48-0 CAPLUS

CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(hydroxymethyl)-3-methylbutyl]-4-[5-methyl-2-(methylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-49-1 CAPLUS

CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-(1H-imidazol-4-ylmethyl)ethyl]-4-[5-methyl-2-(methylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-55-9 CAPLUS

CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[2-[(3-methoxyphenyl)amino]-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-61-7 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 4-[5-cyclohexyl-2-(phenylamino)-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-82-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[5-(hydroxymethyl)-2-(phenylamino)-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-84-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-[(1S,2R)-2-hydroxy-1-methyl-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-99-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-4-pyrimidinyl)-N-(2-hydroxy-2-phenylethyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 449732-00-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-4-pyrimidinyl)-N-[(2S)-2-hydroxy-2-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-02-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-4-pyrimidinyl)-N-[(1S,2R)-2-hydroxy-1-methyl-2-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-03-0 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-4-pyrimidinyl)-N-[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-04-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-(methoxymethyl)-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2003 ACS
AN 2002:348207 CAPLUS
DN 137:72550
TI Accelerating the Drug Optimization Process: Identification, Structure Elucidation, and Quantification of in Vivo Metabolites Using Stable Isotopes with LC/MSn and the Chemiluminescent Nitrogen Detector
AU Taylor, Eric W.; Jia, Weiping; Bush, Mark; Dollinger, Gavin D.
CS Small Molecule Drug Discovery, Chiron Corporation, Emeryville, CA, 94608, USA
SO Analytical Chemistry (2002), 74(13), 3232-3238
CODEN: ANCHAM; ISSN: 0003-2700
PB American Chemical Society
DT Journal
LA English
AB Most preclin. leads exhibit poor ADME/PK (absorption, distribution, excretion and plasma half-life) properties and require optimizing to increase the likelihood of becoming successful pharmaceuticals. As a means of accelerating the evaluation of these leads in vivo, the authors assessed the use of LC/MS with the chemiluminescent-nitrogen detector (CLND) and a stable isotope to identify and quantify in vivo metabolites and to measure excretion. A 14C-labeled preclin. lead that also contained two chlorine atoms was administered orally to rats, and samples of bile, urine, and plasma were collected and analyzed by LC with radiodetection and by LC/MS-CLND with the chlorine atoms used as tracers. Both methods identified seven metabolites in bile and two metabolites in urine. The amt. and abundance of each metabolite was measured, and the results were equiv. for the two methods. Material balance was measured by liq. scintillation counting of the starting samples, by LC/radiodetection, and by LC/MS-CLND. All three methods yielded the same results and showed that the primary route of clearance was metab. followed by immediate excretion. This study demonstrates that LC/MS-CLND with a stable isotope is a method that can efficiently track and accurately quantify metabolites, making it possible to rapidly study ADME/PK in vivo without radiolabeling.
IT **440127-81-1**
RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)
(accelerating drug optimization process by identification and structure elucidation and quantification of in vivo metabolites using stable isotopes with LC/MSn and chemiluminescent nitrogen detector applied to CHIR 99021)
RN 440127-81-1 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[2-[[2-[(5-cyano-2-pyridinyl)amino]ethyl]amino]-4-(2,4-dichlorophenyl)-5-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2003 ACS
AN 2001:635876 CAPLUS
DN 135:211049
TI Preparation of pyrimidinamines and pyridinamines as adenosine receptor modulators for treatment of CNS disorders
IN Borroni, Edilio Maurizio; Huber-Trottmann, Gerda; Kilpatrick, Gavin John; Norcross, Roger David
PA F. Hoffmann La Roche A.-G., Switz.
SO PCT Int. Appl., 256 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001062233	A2	20010830	WO 2001-EP1679	20010215
	WO 2001062233	A3	20020103		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1261327	A2	20021204	EP 2001-927670	20010215
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001008611	A	20030506	BR 2001-8611	20010215
	US 2001027196	A1	20011004	US 2001-788956	20010220
	NO 2002004006	A	20020822	NO 2002-4006	20020822
PRAI	EP 2000-103432	A	20000225		
	WO 2001-EP1679	W	20010215		

OS MARPAT 135:211049
AB The title compds. (I) [wherein A = a bond, S, N(R), (CH2)2, CH:CH, C.tplbond.C, or O; X and Y = independently N:, :N, :CH, C(CN):, :C(CN), C(CSNH2):, or :C(CSNH2), wherein at least 1 of X or Y is N; R1 = H, (cyclo)alkyl, alkenyl, alkynyl, halo, CN, (alkyl)carboxylates, (alkyl)carbamates, alkoxy(alkyl), phenoxy(alkyl), phenylamino(alkyl), (un)substituted phenyl(alkyl) or amino(alkyl), morpholinyl(alkyl), piperidinyl(alkyl), pyridinyl(alkyl), piperazinyl(alkyl), etc.; R2 = H, halo, CN, NO2, acyl, carboxylate, (un)substituted alkyl, alkenyl, alkynyl, or Ph; R3 = alkyl or thienyl, (dihydro)furanyl, benzodioxolyl, isoxazolyl, pyridinyl, dihydropyranyl, pyrazinyl, aryl(alkyl)oxy, pyrazolyl, (un)substituted Ph, etc.; R4 and R5 = independently H, benzoyl, or (un)substituted phenacyl; or A and R2 taken together the with the C atoms to which they are attached may form a substituted thienyl group] were prepd. as adenosine receptor modulators. For example, treating 3,4,5-trimethoxybenzoylacetonitrile with to NaH in DMSO, followed by addn. of CS2 and MeI, gave the bis(methylthio) intermediate. Cycloaddn. with guanidine nitrate in the presence of TEA in DMF afforded the pyrimidinenitrile (II), which exhibited high selectivity toward the A1 and A3 adenosine receptors compared to the A2 receptor with pKi values of 5.88, 5.71 and 7.24, resp. I are useful for the treatment of Alzheimer's disease, Parkinson's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, asthma, allergic responses, hypoxia, ischemia, seizure, substance abuse, and sedation, and they may be

active as muscle relaxants, antipsychotics, antiepileptics, anticonvulsants, and cardioprotective agents (no data). The most preferred indications for I are those which include disorders of the central nervous system, such as certain depressive disorders, neuroprotection, and Parkinson's disease.

IT **357288-99-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrimidinamines and pyridinamines as adenosine receptor modulators for treatment of CNS disorders and other diseases)

RN 357288-99-4 CAPLUS

CN 2-Furancarboxylic acid, 5-[2-amino-5-cyano-6-(methylthio)-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 10 OF 20 CAPLUS COPYRIGHT 2003 ACS
AN 2001:10085 CAPLUS
DN 134:86238
TI Preparation of pyrazole derivatives as antitumor agents
IN Ejima, Akio; Ohsuki, Satoru; Ohki, Hitoshi; Naito, Hiroyuki
PA Daiichi Pharmaceutical Co., Ltd., Japan
SO U.S., 51 pp., Cont.-in-part of Appl. No. PCT/JP98/00300.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6169086	B1	20010102	US 1999-359419	19990723
	WO 9832739	A1	19980730	WO 1998-JP300	19980126
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GM, GW, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 6552018	B1	20030422	US 2000-688787	20001017
PRAI	JP 1997-12116	A	19970127		
	WO 1998-JP300	A2	19980126		
	JP 1998-208807	A	19980724		
	US 1999-359419	A3	19990723		

OS MARPAT 134:86238
AB Title compds. [I; R = CR3:CR4CHR5GZ; R1,R2 = H, halo, OH, alkoxy, NH2, alkylamino, aryl, alkyl; R3,R4 = H, halo, alkoxy, NH2, alkylamino, aryl, alkyl; R5 = H, alkyl, alkenyl, alkynyl, aryl(alkyl); Q = C(:NH)NH2, cycloalkyl, Ph, or monocyclic heterocycle (excluding pyrimidinyl bonded at the 2-position); G = at CHR5-N-attached azacycloalkylidene or -N-Z-attached diazacycloalkylidene; Z = Ph, heterocyclyl, etc.] were prepd. Thus, 2-amino-4,6-dichloropyrimidine was aminated by H2NH2 and the product cyclocondensed with MeCOC(:CHOEt)CO2Et to give I (Q = Z1R6, R1 = H, R2 = Me, Z1 = 2-aminopyrimidine-4,6-diyl)(II; R = CO2Et, R6 = Cl) which was converted in 5 steps to II [R = (E)-CH:CHCHO, R6 = NMe2]. The latter was reductively aminated by 1-(3,5-difluorophenyl)piperazine to give title compd. III. Data for biol. activity of I were given.
IT **210992-71-5P 210992-84-0P 256930-33-3P 316359-45-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of pyrazole derivs. as antitumor agents)
RN 210992-71-5 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-[2-[[(4-methoxyphenyl)methyl]amino]-4-pyrimidinyl]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)

Intermediates — Can not make 103



RN 210992-84-0 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-[2-amino-6-(phenylmethoxy)-4-pyrimidinyl]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 256930-33-3 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-(2-amino-6-chloro-4-pyrimidinyl)-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 316359-45-2 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-[2-amino-6-[[(4-methoxyphenyl)methyl]amino]-4-pyrimidinyl]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 20 CAPLUS COPYRIGHT 2003 ACS
AN 2000:824247 CAPLUS
DN 133:350246
TI Phenylpyridinylimidazoles and (phenylimidazolyl)pyrimidines having cytokine inhibitory activity
IN Liverton, Nigel J.; Claremon, David A.; Theberge, Cory R.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000069848	A1	20001123	WO 2000-US12973	20000511
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6492516	B1	20021210	US 2000-564272	20000504
	EP 1180101	A1	20020220	EP 2000-932319	20000511
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	US 1999-134164P	P	19990514		
	WO 2000-US12973	W	20000511		

OS MARPAT 133:350246
AB Title compds. I (Y = OH, alkoxy, substituted amino, etc.; R3 = H, aralkylamino, alkylamino, etc.; R4, R5, R6 = H, halo, OH, CF3, NH2, etc.; Q = CH, N) were prepd. Thus, I [Y = EtO, R3 = (S)-(.alpha.-methylbenzyl)amino, R4 = R5 = H, R6 = CF3, Q = N] was prepd. in 4 steps starting from 3-(trifluoromethyl)benzamidoxime and Et propiolate.
IT **306297-38-1P 306297-40-5P 306297-43-8P**
306297-45-0P 306297-48-3P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
((phenylimidazolyl)pyrimidines having cytokine inhibitory activity)
RN 306297-38-1 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 1-[2-[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-2-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 306297-40-5 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 1-[2-[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 306297-43-8 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[1-[2-[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-2-[3-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 306297-45-0 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-phenyl-1-[2-[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 306297-48-3 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-phenyl-1-[2-[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **306297-54-1P 306297-59-6P 306297-62-1P**
306297-68-7P 306297-71-2P 306297-74-5P
306297-77-8P 306297-82-5P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
((phenylimidazolyl)pyrimidines having cytokine inhibitory activity)
RN 306297-54-1 CAPLUS
CN 1H-Imidazole-4-carboxamide, 1-[2-[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-N-4-piperidinyl-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 306297-59-6 CAPLUS
CN 1H-Imidazole-4-carboxamide, N-[2-(dimethylamino)ethyl]-1-[2-[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 306297-62-1 CAPLUS
CN 1H-Imidazole-4-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-1-[2-[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 306297-68-7 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 1-[2-[(1,1-dimethylethyl)amino]-4-pyrimidinyl]-2-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 306297-71-2 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 1-[2-(cyclobutylamino)-4-pyrimidinyl]-2-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 306297-74-5 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 1-[2-[[2-(2-chlorophenyl)ethyl]amino]-4-pyrimidinyl]-2-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 306297-77-8 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 1-[2-[[(2-fluorophenyl)methyl]amino]-4-pyrimidinyl]-2-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 306297-82-5 CAPLUS
CN 1H-Imidazole-4-carboxamide, N-[2-(dimethylamino)ethyl]-2-phenyl-1-[2-[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2003 ACS
AN 2000:157715 CAPLUS
DN 132:194285
TI Preparation of [(sulfonamidooxopyrrolidino)methyl]benzamidines as factor Xa inhibitors
IN Ewing, William R.; Becker, Michael R.; Choi-Sledeski, Yong Mi; Pauls, Heinz W.; McGarry, Daniel G.; Davis, Roderick S.; Spada, Alfred P.
PA Rhone-Poulenc Rorer Pharmaceuticals, Inc., USA
SO U.S., 47 pp., Cont.-in-part of U.S. 5,731,315.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6034093	A	20000307	US 1998-130336	19980806
	US 5612353	A	19970318	US 1995-481024	19950607
	WO 9640679	A1	19961219	WO 1996-US9816	19960607
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
	US 5731315	A	19980324	US 1996-761414	19961206
	US 5958918	A	19990928	US 1997-976034	19971121
	WO 9824784	A1	19980611	WO 1997-US22414	19971201
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
PRAI	US 1995-481024	A2	19950607		
	WO 1996-US9816	A2	19960607		
	US 1996-761414	A2	19961206		
	US 1997-976034	A2	19971121		
	WO 1997-US22414	A2	19971201		
	WO 1996-US1816	A1	19960607		

OS MARPAT 132:194285
AB R4NHZZ1(CH2)nZ2NRSO2R1 [I; R,R4 = H, (un)substituted alkyl, -(hetero)arylalkyl, etc.; R1 = (un)substituted thienyl or -Ph; Z = CH2 or C(:NR5); R5 = R1 = (un)substituted thienyl or -Ph; z1 = (un)substituted phenylene or -heteroarylene; Z2 = (un)substituted 1,3-cyclobutylene, -pyrrolidinediyl, -piperidinediyl, etc.; n = 0-3] were prepd. Thus, (S)-H2NCH2CH2CH(NHCO2CMe3)CO2H was lactamized and the product N-alkylated by 3-(NC)C6H4CH2Br to give, after deprotection, (S)-3-(3-amino-2-oxo-1-pyrrolidinyl)benzonitrile which was amidated by benzo[b]thiophene-2-sulfonyl chloride (prepn. given) and the product treated with HCl/EtOH/NH3 to give title compd. (S)-II. Data for biol. activity of I were given.
IT **205054-21-3P 205054-23-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of [(sulfonamidooxopyrrolidino)methyl]benzamidines as factor Xa inhibitors)

RN 205054-21-3 CAPLUS
CN Benzenecarboximidamide, 3-[[(3S)-3-[[[5-(2-amino-4-pyrimidinyl)-2-thienyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]methyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 205054-20-2
CMF C20 H21 N7 O3 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 205054-23-5 CAPLUS
CN Benzenecarboximidamide, 3-[[(3S)-3-[[[5-(2-amino-4-pyrimidinyl)-2-thienyl]sulfonyl]methylamino]-2-oxo-1-pyrrolidinyl]methyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 205054-22-4
CMF C21 H23 N7 O3 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT **205055-76-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of [(sulfonamidooxopyrrolidino)methyl]benzamidines as factor Xa inhibitors)
RN 205055-76-1 CAPLUS
CN 2-Thiophenesulfonamide, 5-(2-amino-4-pyrimidinyl)-N-[(3S)-1-[(3-cyanophenyl)methyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2003 ACS
AN 2000:84798 CAPLUS
DN 132:137383
TI Preparation of pyrazole derivatives as antitumor agents
IN Ejima, Akio; Ohsuki, Satoru; Ohki, Hitoshi; Naito, Hiroyuki; Makino, Chie
PA Daiichi Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 189 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000005230	A1	20000203	WO 1999-JP3962	19990723
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9948002	A1	20000214	AU 1999-48002	19990723
	EP 1103551	A1	20010530	EP 1999-931515	19990723
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2000169475	A2	20000620	JP 1999-211211	19990726
	NO 2001000405	A	20010322	NO 2001-405	20010123
	US 6573377	B1	20030603	US 2001-744428	20010124
PRAI	JP 1998-208807	A	19980724		
	JP 1998-274459	A	19980929		
	WO 1999-JP3962	W	19990723		

OS MARPAT 132:137383
AB The title compds. I [R1 = H, halo, etc.; R2 = H, halo, OH, etc.; R3 = H, amino, alkoxy, etc.; R4 = H, halo, alkylamino, etc.; R5 = H, alkyl, etc.; Q = heterocyclic ring, etc.; G = heterocyclic ring (further details on said ring are given)] are prepd. Compds. of this invention in vitro showed IC50 values of 0.6 ng/mL to 35 ng/mL against the growth of lung tumor cells.
IT **256930-33-3P 256930-74-2P 256931-29-0P 256931-34-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of pyrazole derivs. as antitumor agents)
RN 256930-33-3 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-(2-amino-6-chloro-4-pyrimidinyl)-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 256930-74-2 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-(2-amino-6-chloro-5-methoxy-4-pyrimidinyl)-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 256931-29-0 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-[6-chloro-2-[[(4-methoxyphenyl)methyl]amino]-4-pyrimidinyl]-5-ethyl-, methyl ester (9CI) (CA INDEX NAME)



RN 256931-34-7 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-(2-amino-6-chloro-4-pyrimidinyl)-5-ethyl-, methyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2003 ACS
AN 1998:527319 CAPLUS
DN 129:161560
TI Preparation of pyrazole derivatives as antitumor agents
IN Ejima, Akio; Ohsuki, Satoru
PA Daiichi Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 90 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9832739	A1	19980730	WO 1998-JP300	19980126
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GM, GW, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9855771	A1	19980818	AU 1998-55771	19980126
	AU 724394	B2	20000921		
	EP 1022270	A1	20000726	EP 1998-900736	19980126
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	TW 486478	B	20020511	TW 1998-87101177	19980126
	CN 1105707	B	20030416	CN 1998-803733	19980126
	US 6169086	B1	20010102	US 1999-359419	19990723
	NO 9903628	A	19990922	NO 1999-3628	19990726
	US 6552018	B1	20030422	US 2000-688787	20001017
PRAI	JP 1997-12116	A	19970127		
	WO 1998-JP300	W	19980126		
	JP 1998-208807	A	19980724		
	US 1999-359419	A3	19990723		

OS MARPAT 129:161560
AB The title compds. [I; R1 and R2 each is hydrogen, halo, hydroxy, alkoxy, amino, alkylamino, aryl, or alkyl; R3 and R4 each is hydrogen, halo, alkoxy, amino, alkylamino, aryl, or alkyl; R5 is hydrogen, alkyl, alkenyl, alkynyl, aryl, or arylalkyl; Q is amidino, cycloalkyl, Ph, or monocyclic heterocycle (excluding pyrimidinyl bonded at the 2-position); G is a nitrogenous satd. heterocyclyl; Z is Ph, heterocycle, etc.] are prepd. I are useful as antitumor agents. Thus, compd. (II; W = COCH2) (prepn. given) was treated with NaBH4 and refluxed with p-TsOH in THF and treated with 1N HCl to give the title compd. II.HCl (W = CH:CH), which showed GI50 of 10.6 ng/mL when tested with PC-6 tumor cell.
IT **210992-71-5P 210992-84-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of pyrazole derivs. as antitumor agents)
RN 210992-71-5 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-[2-[[(4-methoxyphenyl)methyl]amino]-4-pyrimidinyl]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 210992-84-0 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-[2-amino-6-(phenylmethoxy)-4-pyrimidinyl]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2003 ACS
AN 1998:192127 CAPLUS
DN 128:243948
TI Preparation of heterocyclylsulfonylaminooxopyrrolidinylmethylbenzamidines and related compounds as Factor Xa inhibitors.
IN Ewing, William R.; Becker, Michael R.; Choi-Sledeski, Yong Mi; Pauls, Heinz W.; McGarry, Daniel G.; Davis, Roderick S.; Spada, Alfred P.
PA Rhone-Poulenc Rorer Pharmaceuticals Inc., USA
SO U.S., 36 pp., Cont.-in-part of U.S. 5,612,353.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5731315	A	19980324	US 1996-761414	19961206
	US 5612353	A	19970318	US 1995-481024	19950607
	CA 2223403	AA	19961219	CA 1996-2223403	19960607
	CA 2223403	C	20020423		
	CN 1190395	A	19980812	CN 1996-194489	19960607
	CA 2245699	AA	19980611	CA 1997-2245699	19971201
	WO 9824784	A1	19980611	WO 1997-US22414	19971201
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9860121	A1	19980629	AU 1998-60121	19971201
	AU 727810	B2	20001221		
	EP 894088	A1	19990203	EP 1997-954779	19971201
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	CN 1213370	A	19990407	CN 1997-192888	19971201
	CN 1093856	B	20021106		
	BR 9707489	A	19990727	BR 1997-7489	19971201
	AP 800	A	20000119	AP 1998-1305	19971201
	W: GH, KE, LS, MW, SD, SZ, UG, ZW				
	JP 2000505815	T2	20000516	JP 1998-525861	19971201
	ZA 9710968	A	19980722	ZA 1997-10968	19971205
	NO 9803603	A	19981005	NO 1998-3603	19980805
	US 6034093	A	20000307	US 1998-130336	19980806
	CN 1418882	A	20030521	CN 2002-103157	20020201
PRAI	US 1995-481024	A2	19950607		
	WO 1996-US9816	A2	19960607		
	US 1996-761414	A	19961206		
	US 1997-976034	A2	19971121		
	WO 1997-US22414	W	19971201		

OS MARPAT 128:243948
AB Title compds. [I; Ar1 = Ph, monocyclic heteroaryl; R = H, (substituted) alkyl, aralkyl, heteroaralkyl, R6O(CH2)x, R6O2C(CH2)x, Y1Y2NCO(CH2)x, Y1Y2N(CH2)x; R1 = H, alkyl, OH, alkoxy, Y1Y2N, halo, CO2R6, CONY1Y2, (CH2)xOR6, (CH2)xNY1Y2, CN; R2, R3 = H, OH, alkoxy, Y1Y2N, halo, CO2R6, CONY1Y2, (CH2)xOR6, (CH2)xNY1Y2, cyano, (substituted) alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, etc.; R4 = H, (substituted) alkyl, aralkyl, heteroaralkyl; X1, X11 = H, (substituted) alkyl, aryl, aralkyl,

heteroaryl, heteroaralkyl; X1X11 = O; X2, X21 = H; X2X21 = O; X3 = H, OH, (substituted) alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl; X3X1 or X3X11 = atoms to form a 4-7 membered cycloalkyl, heterocyclyl ring; X4 = H, (substituted) alkyl, aralkyl; X5, X51 = H; X5X51 = NR5; R5 = H, R6O2C, R6O, cyano, R6CO, (substituted) alkyl, NO2, Y1Y2N; Y1, Y2 = H, (substituted) alkyl, aryl, aralkyl, heteroaralkyl; Y1Y2N = 4-7 membered heterocyclyl; X6, X61 = H, R7R8N, R9O, R7R8NCO, R7R8NSO2, R7R8NSO2N, R7R8SO2O, R9CO, CO2R6, CONY1Y2, (CH2)xCO2R6, (CH2)xCONY1Y2, (CH2)xOR6, (CH2)xNY1Y2, halo, cyano, NO2; R6 = H, (substituted) alkyl, aralkyl, heteroaralkyl; R7, R8 = H, (substituted) alkyl, etc.; R9 = H, (substituted) alkyl, acyl, etc.; m, n = 0-3; x = 1-5], were prepd. as antithrombotics. Thus, 3-[3-(S)-amino-2-oxopyrrolidin-1-ylmethyl]benzonitrile hydrochloride (prepn. given), benzo[b]thiophene-2-sulfonyl chloride (prepn. given), and Et3N were stirred in CH2Cl2 to give benzo[b]thiophene-2-sulfonic acid [1-(3-cyanobenzyl)-2-oxopyrrolidin-3-(S)-yl]amide. The latter in EtOH/CH2Cl2 was treated with HCl to give a residue which in MeOH was treated with NH3 to give 3-[3-(S)-(benzo[b]thiophene-2-sulfonylamino)-2-oxopyrrolidin-1-ylmethyl]benzamidine trifluoroacetate.

IT **205054-21-3P 205054-23-5P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heterocyclylsulfonylaminooxopyrrolidinylmethylbenzamidines and related compds. as Factor Xa inhibitors)

RN 205054-21-3 CAPLUS

CN Benzenecarboximidamide, 3-[[(3S)-3-[[[5-(2-amino-4-pyrimidinyl)-2-thienyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]methyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 205054-20-2
CMF C20 H21 N7 O3 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 205054-23-5 CAPLUS
CN Benzenecarboximidamide, 3-[[(3S)-3-[[[5-(2-amino-4-pyrimidinyl)-2-thienyl]sulfonyl]methylamino]-2-oxo-1-pyrrolidinyl]methyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 205054-22-4
CMF C21 H23 N7 O3 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT **205055-76-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of heterocyclylsulfonylaminooxopyrrolidinylmethylbenzamidines and related compds. as Factor Xa inhibitors)
RN 205055-76-1 CAPLUS
CN 2-Thiophenesulfonamide, 5-(2-amino-4-pyrimidinyl)-N-[(3S)-1-[(3-cyanophenyl)methyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2003 ACS
AN 1993:147494 CAPLUS
DN 118:147494
TI The chemistry of 5-oxodihydroisoxazoles. III. Synthesis of further annelated pyrimidines
AU Prager, Rolf H.; Rosenzweig, Teresa K.; Singh, Yogendra
CS Sch. Phys. Sci., Flinders Univ. South Australia, Adelaide, 5001, Australia
SO Australian Journal of Chemistry (1992), 45(11), 1825-32
CODEN: AJCHAS; ISSN: 0004-9425
DT Journal
LA English
OS CASREACT 118:147494
AB The synthesis of some 2-heterocyclyl-5-oxo-2,5-dihydroisoxazole-4-carboxylates is reported, where the heterocycle is pyridin-2-yl, triazin-2-yl (I), pyrimidin-4-yl (II), quinolin-2-yl (III) (R1 = H, OMe; R2 = Me, Ph), or phthalazin-1-yl (IV), as is their base-catalyzed rearrangement to the corresponding annelated pyrimidines.
IT **145771-17-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and base-induced rearrangement of)
RN 145771-17-1 CAPLUS
CN 4-Isoxazolecarboxylic acid, 2-(2,6-diamino-4-pyrimidinyl)-2,5-dihydro-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2003 ACS
AN 1992:448481 CAPLUS
DN 117:48481
TI Synthesis of some new heterocyclic compounds derived from 2-amino-4-hydrazino-6-substituted pyrimidines
AU Seada, M.; Abdel-Rahman, R. M.; El-Behairy, M.; Hanafy, Fatin
CS Fac. Educat., Ain Shams Univ., Roxy, Egypt
SO Asian Journal of Chemistry (1992), 4(3), 604-14
CODEN: AJCHEW; ISSN: 0970-7077
DT Journal
LA English
AB A no. of new heterocyclic compds. contg. 2-amino-6-substituted pyrimidin-4-yl moiety were prepd. from the reactions of 2-amino-4-hydrazinopyrimidines I (R = Cl, Me). The structures of the prepd. compds. were established by elemental and spectral anal.
IT **93351-00-9P 142077-31-4P 142077-32-5P 142077-33-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 93351-00-9 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 5-amino-1-(2-amino-6-methyl-4-pyrimidinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 142077-31-4 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-(2-amino-6-chloro-4-pyrimidinyl)-4,5-dihydro-3-methyl-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 142077-32-5 CAPLUS
CN 3-Pyridazinecarboxylic acid, 1-(2-amino-6-chloro-4-pyrimidinyl)-1,4,5,6-tetrahydro-6-oxo- (9CI) (CA INDEX NAME)



RN 142077-33-6 CAPLUS
CN 3-Pyridazinecarboxylic acid, 1-(2-amino-6-methyl-4-pyrimidinyl)-1,4,5,6-tetrahydro-6-oxo- (9CI) (CA INDEX NAME)



L4 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2003 ACS
AN 1972:540047 CAPLUS
DN 77:140047
TI Synthetic penicillins
IN Saikawa, Isamu; Hori, Takako; Maeda, Toyoo; Osada, Tamiko; Momoi, Kaishu; Sakamoto, Mayumi; Watanabe, Isao; Fujii, Fumiko; Miyajima, Hitoko
PA Toyama Chemical Industry Co., Ltd.
SO Jpn. Tokkyo Koho, 5 pp.
CODEN: JAXXAD
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 47029918	B4	19720804	JP 1969-104304	19691226

AB The title compds. (I), antibacterials stable against an acid, were prepd. by treating 6-aminopenicillanic acid (II) with 5-substituted 1,2,4-oxadiazole-3-carboxylic acid derivs. E.g., 5-methyl-1,2,4-oxadiazole-3-carbonyl azide in AcOEt was treated with 1.6 g II, NEt3, in CH2Cl2 to give 0.23 g I (R = Me). (R = Ph, 4-OMeC6H4, 2-furyl, 4-pyridyl, 2-amino-5-pyrimidyl) were similarly prepd.

IT **38030-11-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 38030-11-4 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[5-(2-amino-5-pyrimidinyl)-1,2,4-oxadiazol-3-yl]carbonyl]amino]-3,3-dimethyl-7-oxo-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 19 OF 20 CAPLUS COPYRIGHT 2003 ACS
AN 1964:440468 CAPLUS
DN 61:40468
OREF 61:7025f-h,7026a-d
TI 4-(1-Pyrazolyl)pyrimidines
IN Shirakawa, Kenzo; Tsujikawa, Teruaki
PA Takeda Chemical Industries, Ltd.
SO 6 pp.
DT Patent
LA Unavailable

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 39005040		19640420	JP	19600330

AB A mixt. of 2-amino-4-hydrazino-6-methylpyrimidine 1.4, H2O 30, and acetylacetone 1.1 parts is boiled 15 min. to give 1.7 parts 2-amino-4-(3,5-dimethyl-1-pyrazolyl)-6-methylpyrimidine, columns, m. 114-16.degree. (ligroine). Similarly prepd. are: 2-amino-4-(4-cyano-5-amino-1-pyrazolyl)-6-methylpyrimidine (needles, m. 246-7.degree.); 2-amino-4-(4-ethoxycarbonyl-5-amino-1-pyrazolyl)-6-methylpyrimidine [needles, m. 200-2.degree. (dil. EtOH)]; 2-amino-4-(4-ethoxycarbonyl-5-methyl-1-pyrazolyl)-6-methylpyrimidine [plates, m. 153-5.degree. (dil. EtOH)]; 2-anilino-4-(3,5-dimethyl-1-pyrazolyl)-6-methylpyrimidine [plates, m. 112-13.degree. (ligroine)]; 2-anilino-4-(4-cyano-5-amino-1-pyrazolyl)-6-methylpyrimidine [needles, m. 267-9.degree. (ethylene glycol monomethyl ether)]; 2-anilino-4-(4-ethoxycarbonyl - 5 - methyl - 1 - pyrazolyl - 6 - methylpyrimidine [columns, m. 135-6.5.degree. (80% EtOH)]; 2-benzylamino-4-(3,5-dimethyl-1-pyrazolyl)-6-methylpyrimidine (needles, m. 142.5-3.5.degree.); 2-benzylamino-4-(4-ethoxycarbonyl-5-methyl-1-pyrazolyl)-6-methylpyrimidine [plates, m. 143.5-5.degree. (C6H6-ligroine)]; 2-benzylamino-4-(4-ethoxycarbonyl-5-amino-1-pyrazolyl)-6-methylpyrimidine [flakes, m. 148-50.degree. (dil. EtOH)]; 2-benzylamino-4-(4-cyano-5-amino-1-pyrazolyl)-6-methylpyrimidine (columns, m. 203-5.degree.); 2-methylthio-4-(3,5-dimethyl-1-pyrazolyl)-6-methylpyrimidine [needles, m. 103-4.degree. (dioxane-H2O)]; 2-methylthio-4-(4-cyano-5-amino - 1 - pyrazolyl) - 6 - methylpyrimidine [needles, m. 239-40.degree. (dioxane-H2O)]; 2,4-bis(3,5-dimethyl-1-pyrazolyl)-5,6-trimethylenepyrimidine [needles, m. 113-14.degree. (ligroine)]; 2-(3,5-dimethyl-1-pyrazolyl)- 4- (4- ethoxycarbonyl-5-amino-1-pyrazolyl)-5,6-trimethylenepyrimidine [columns, m. 182-3.degree. (ethylene glycol monomethyl ether)]; 2-(3,5-dimethyl-1-pyrazolyl)-4-(4-cyano- 5-amino- 1-pyrazolyl)- 5,6-trimethylenepyrimidine [granules, m. 249-52.degree. (dil. AcOH)]; 2-(3,5-dimethyl-1-pyrazolyl)-4-(4-ethoxycarbonyl-5-methyl- 1 - pyrazolyl) - 5,6-trimethylenepyrimidine [plates, m. 159.5-61.degree. (C6H6)]; 2,4-bis-(3,5-dimethyl-1-pyrazolyl)-6-methylpyrimidine [needles, m. 117-19.degree. (dil. EtOH)]; 2-(3,5-dimethyl-1-pyrazolyl)-4-(4-cyano-5-amino-1-pyrazolyl)-6-methylpyrimidine [needles, m. 245-7.degree. (AcOH)]; 2-(3,5-dimethyl-1-pyrazolyl)-4-(4-ethoxycarbonyl-5-amino-1-pyrazolyl)-6-methylpyrimidine [needles, m. 177-9.degree. (AcOH)]; 2-(3,5-dimethyl-1-pyrazolyl)-4-(4-ethoxycarbonyl-5-methyl-1-pyrazolyl)-6-methylpyrimidine [m. 160-1.degree. (dil. AcOH)]; 2,4-bis(3,5-dimethyl- 1 - pyrazolyl)- 6- phenylpyrimidine [needles, m. 153-4.degree. (dil. EtOH)]; 2-(3,5-dimethyl-1-pyrazolyl)-4-(4-cyano-5-amino-1-pyrazolyl)-6-phenylpyrimidine [needles, m. 242-3.degree. (AcOH)]; 2-(3,5-dimethyl-1-pyrazolyl)-4-(4-ethoxycarbonyl-5-methyl-1-pyrazolyl)-6-(phenylpyrimidine [needles m. 165-6.degree. (AcOH)]; 2-(3,5-dimethyl-1-pyrazolyl)-4-(4-ethoxycar-bonyl-5-amino-1-pyrazolyl)-6-phenylpyrimidine [needles m. 187-8.degree. (AcOH)]; 2-(3,5-dimethyl-1-pyrazolyl)-4-(4-ethoxycarbonyl-5-methyl-1-pyrazolyl)-5,6-

tetramethylenepyrimidine [needles, m. 130-3.degree. (dil. AcOH)]; 2-(3,5-dimethyl-1-pyrazolyl)-4-(4-ethoxycarbonyl - 5- amino- 1 - pyrazolyl) - 5,6 - tetramethylpyrimidine [flakes, m. 197-8.degree. (BuOH)]; 2,4-bis(3,5-dimethyl-1-pyrazolyl)-5,6-tetramethylenepyrimidine [m. 130.degree. (dil. AcOH)]; 2-(3,5 - dimethyl - 1 - pyrazolyl) - 5,6 - tetramethylenepyrimidine [needles, m. 225.degree. (AcOH)]; 2-anilino-4-(4-ethoxycarbonyl-5-amino-1-pyrazolyl)-6-methylpyrimidine [m. 146-7.degree. (dil. AcOH)]; 2 - hydroxy - 4 - (3,5 - dimethyl - 1 - pyrazolyl)pyrimidine [columns, m. 288-9.degree. (dil. EtOH)]; 2-hydroxy-4-(4-cyano-5-amino-1-pyrazolyl)-6-methylpyrimidine [needles, m. >300.degree. (Me Cellosolve)]; 2-hydroxy-4-(4-ethoxycarbonyl-5-amino-1-pyrazolyl)-6-methylpyrimidine [needles, m. 298.degree. (Me Cellosolve)]; 2-amino-4-(3-methyl-5-phenyl-1 - pyrazolyl)- 6-methylpyrimidine [needles, m. 189-90.degree. (dil. EtOH)]; 2-amino-4-(4-ethoxycarbonyl-5-phenyl-1-pyrazolyl)-6-methylpyrimidine [columns m. 144-5.degree. (dil. EtOH)]. The products are useful as antituberculous, antitumor, and antispasmodic drugs.

IT **91644-40-5**, Pyrazole-4-carboxylic acid, 1-(2-amino-6-methyl-4-pyrimidinyl)-5-methyl-, ethyl ester **92555-72-1**, Pyrazole-4-carboxylic acid, 1-(2-amino-6-methyl-4-pyrimidinyl)-5-phenyl- **93351-00-9**, Pyrazole-4-carboxylic acid, 5-amino-1-(2-amino-6-methyl-4-pyrimidinyl)-, ethyl ester **93871-87-5**, Pyrazole-4-carboxylic acid, 1-(2-anilino-6-methyl-4-pyrimidinyl)-5-methyl-, ethyl ester **94069-65-5**, Pyrazole-4-carboxylic acid, 5-amino-1-[2-(benzylamino)-6-methyl-4-pyrimidinyl]-, ethyl ester **94378-89-9**, Pyrazole-4-carboxylic acid, 1-[2-(benzylamino)-6-methyl-4-pyrimidinyl]-5-methyl-, ethyl ester **94711-75-8**, Pyrazole-4-carboxylic acid, 5-amino-1-(2-anilino-6-methyl-4-pyrimidinyl)-, ethyl ester
(prepn. of)

RN 91644-40-5 CAPLUS

CN Pyrazole-4-carboxylic acid, 1-(2-amino-6-methyl-4-pyrimidinyl)-5-methyl-, ethyl ester (7CI) (CA INDEX NAME)



RN 92555-72-1 CAPLUS

CN Pyrazole-4-carboxylic acid, 1-(2-amino-6-methyl-4-pyrimidinyl)-5-phenyl- (7CI) (CA INDEX NAME)



RN 93351-00-9 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 5-amino-1-(2-amino-6-methyl-4-pyrimidinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 93871-87-5 CAPLUS
CN Pyrazole-4-carboxylic acid, 1-(2-anilino-6-methyl-4-pyrimidinyl)-5-methyl-, ethyl ester (7CI) (CA INDEX NAME)



RN 94069-65-5 CAPLUS
CN Pyrazole-4-carboxylic acid, 5-amino-1-[2-(benzylamino)-6-methyl-4-pyrimidinyl]-, ethyl ester (7CI) (CA INDEX NAME)



RN 94378-89-9 CAPLUS
CN Pyrazole-4-carboxylic acid, 1-[2-(benzylamino)-6-methyl-4-pyrimidinyl]-5-methyl-, ethyl ester (7CI) (CA INDEX NAME)



RN 94711-75-8 CAPLUS
CN Pyrazole-4-carboxylic acid, 5-amino-1-(2-anilino-6-methyl-4-pyrimidinyl)-, ethyl ester (7CI) (CA INDEX NAME)


PhNH
N
N
N
N
Me
H2N
C—OEt
O

L4 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2003 ACS
AN 1964:68217 CAPLUS
DN 60:68217
OREF 60:12009h,12010a-h,12011a-c
TI Pyrimidine derivatives. XII. 2-(1-Pyrazolyl)pyrimidines. 2
AU Shirakawa, Kenzo; Tsujikawa, Teruaki
CS Takeda Res. Lab., Osaka, Japan
SO Takeda Kenkyusho Nenpo (1963), 22, 27-46
CODEN: TDKNAF; ISSN: 0371-5973
DT Journal
LA Unavailable
AB Boiling of a mixt. of 8 g. 2-(4-ethoxycarbonyl-5-methyl-1-pyrazolyl)-4-hydroxy-6-phenylpyrimidine, 70 cc. 4% NaOH, and 70 cc. EtOH for 30 min. gives 60.3% 2-(4-carboxy-5-methyl-1-pyrazolyl)-4-hydroxy-6-phenylpyrimidine, m. 320.degree. (decompn.) (AcOH). Similarly prepd. are 2-(4-carboxy-5-amino-1-pyrazolyl)-4-hydroxy-6-methylpyrimidine [m. 229.degree. (decompn.) (dil. AcOH)], 2-(4-carboxy-5-amino-1-pyrazolyl)-4-hydroxy-5,6-tetramethylenepyrimidine [m. 250.degree. (decompn.) (EtOCH2CH2OH)], and 2-(3,5-dimethyl-1-pyrazolyl)-4-hydroxy-5-carboxypyrimidine [m. 255.degree. (decompn.) (MeOCH2CH2OH)] in 64%, 17%, and 34.4% yields, resp. They are dissolved in CHCl3 and treated with Cl or Br to give corresponding chlorinated or brominated products: (product, m.p., and % yield given): 2-(3,5-dimethyl-4-chloro-1-pyrazolyl)-4-hydroxy-5-chloro-6-methylpyrimidine, 248-51.degree. (EtOH), 52.2; 2-(3,5-dimethyl-4-bromo-1-pyrazolyl)-4-hydroxy-5-bromo-6-methylpyrimidine, 246-8.degree. (dil. AcOH), 83; 2-(3,5-dimethyl-4-bromo-1-pyrazolyl)-4-hydroxy-5-bromo-6-phenylpyrimidine, 150-1.degree. (CHCl3), 83; 2-(3-methyl-4-bromo-5-phenyl-1-pyrazolyl)-4-hydroxy-5-bromo-6-phenylpyrimidine, 229-31.degree. (PhMe), 67.3; 2-(4-ethoxycarbonyl-5-methyl-1-pyrazolyl)-4-hydroxy-5-bromo-6-phenylpyrimidine, 167-9.degree. (dil. EtOH), 85.8%. 4-Hydroxy compds. are treated with POCl3 to give 4-Cl compds. Thus, the following I are prepd. (R, R1, m.p., and % yield given): H, Me, 57.degree. (dil. EtOH), 55; (RR1=) (CH2)3, 131-3.degree. (C6H6-ligroine), 95.5; (RR1=) (CH2)4, 130-2.degree. (ligroine), 58; H, Ph, 117-18.degree. (dil. EtOH), 89. Reaction of I with NH2NH2.H2O gives II (R, R1, m.p., and % yield given): H, Me, 183-4.degree. (BuOH), 72.5; (RR1=) (CH2)3, 1857.degree. (dil. EtOH), 83.5; (RR1=) (CH2)4, 128-32.degree. (dil. EtOH), 81.2; H, Ph, 206-7.degree. (BuOH), 66. The synthesis of the following III is also reported (R, R1, R2, R3, R4, appearance, and m.p. given): Me, H, Me, NH2, Me, prisms, 114-16.degree. (ligroine); Me, H, Me, NHPh, Me, plates, 112-13.degree. (ligroine); Me, H, Me, NHCH2Ph, Me, needles, 142.5-3.5.degree. (dil. EtOH); Me, H, Me, SMe, Me, needles, 103-4.degree. (dil. dioxane); Me, H, Me, Me, NH2, needles, 120-3.degree. (MeOCH2CH2OH); Me, H, Me, OH, Me, prisms, 288-9.degree. (decompn.) (EtOH); H, CO2Et, Me, NH2, Me, plates, 153-5.degree. (dil. EtOH); H, CO2Et, Me, NHPh, Me, prisms, 135-6.5.degree. (80% EtOH); H, CO2Et, Me, NHCH2Ph, Me, plates, 143.5-5.degree. (C6H6-ligroine); H, CO2Et, Ph, NH2, Me, prisms, 144-5.degree. (dil. EtOH); H, CO2Et, NH2, NH2, Me, needles, 200-2.degree. (70% EtOH); H, CO2Et, NH2, NHPh, Me, needles, 146-7.degree. (dil. AcOH); H, CO2Et, NH2, NHCH2Ph, Me, leaflets, 148-50.degree. (50% EtOH); H, CO2Et, NH2, OH, Me, needles, 298.degree. (decompn.) (MeOCH2CH2OH); H, CN, NH2, NH2, Me, needles, 251-2.degree. (80% EtOH); H, CN, NH2, NHPh, Me, needles, 2679.degree. (EtOCH2CH2OH); H, CN, NH2, NHCH2Ph, Me, prisms, 203-5.degree. (60% AcOH); H, CN, NH2, SMe, Me, needles, 239-40.degree. (dil. dioxane); H, CN, NH2, OH, Me, needles, >300.degree. (MeOCH2CH2OH). IV are also prepd. (same data): Me, H, Me, H, Me, needles, 117-19.degree. (80% EtOH); Me, H, Me, (R3R4=) (CH2)3, needles, 113-14.degree. (ligroine); Me, H, Me, (R3R4=)(CH2)4, powder,

103.degree. (dil. AcOH); Me, H, Me, H, Ph, needles, 153-4.degree. (80% EtOH); H, CO2Et, Me, H, Me, prisms, 160-1.degree. (dil. AcOH); H, CO2Et, Me, (R3R4=) (CH2)3, plates, 159.5-61.degree. (C6H6); H, CO2Et, Me, (R3R4=) (CH2)4, needles, 130-3.degree. (dil. AcOH); H, CO2Et, Me, H, Ph, needles, 165-6.degree. (AcOH); H, CO2Et, NH2, H, Me, needles, 177-9.degree. (AcOH); H, CO2Et, NH2, (R3R4=) (CH2)3, prisms, 182-3.degree. (EtOCH2CH2OH); H, CO2Et, NH2, (R3R4=) (CH2)4, leaflets, 197-8.degree. (BuOH); H, CO2Et, NH2, H, Ph, needles, 187-8.degree. (AcOH); H, CN, NH2, H, Me, needles, 245-7.degree. (AcOH); H, CN, NH2, (R3R4=) (CH2)3, powder, 249-50.degree. (dil. AcOH); H, CN, NH2, (R3R4=) (CH2)4, needles, 225.degree. (AcOH); H, CN, NH2, H, Ph, needles, 242-3.degree. (AcOH). The following V are prepd. (R, R1, R2, R3, and m.p. given): 2-pyridyl, H, CO2Et, NH2, 93-5.degree. (ligroine); 2-pyridyl, H, CN, NH2, 186-9.degree. (EtCH2CH2OH); a, Me, H, Me, 165-7.degree. (MeOCH2CH2OH); a, H, CO2Et, Me, 160-2.degree. (MeOCH2CH2OH); a, H, CO2Et, NH2, >300.degree. (MeOCH2CH2OH); a, H, CN, NH2, >300.degree. (MeOCH2CH2OH); b, H, CO2Et, NH2, 216.degree. (decompn.) (MeOCH2CH2OH); c, Me, H, Me, 104-5.degree. (MeOCH2CH2OH); c, H, CO2Et, NH2, 132-5.degree. (MeOCH2CH2OH); d, Me, H, Me, 106-9.degree. (MeOCH2CH2OH); e, Me, H, Me, 123-4.degree. (EtOH); f, Me, H, Me, 132-3.degree. (EtOH); g, Me, H, Me, 143-5.degree. (dil. EtOH); h, H, CO2Et, NH2, 130-1.degree. (MeOH); i, H, CO2Et, NH2, 88.degree. (EtOH); j, Me, H, Me, 237.degree. (dil. EtOH); k, Me, H, Me, 68-70(EtOH); l, Me, H, Me, -(oil, b4 204.degree.); m. H, CO2Et, NH2, 278.degree. (decompn.) (MeOCH2CH2OH); o-MeOC6H4, Me, H, Me, -(oil. b14 161-4.degree.): p-H2NO2SC6H4, Me, H. Me, 228-30.degree. (MeOCH2CH2OH); m-HO3SC6H4, Me, H, Me, 313.degree. (decompn.) (dil. EtOH); p-HO2CCH2C6H4, Me, H, Me, 151-2.5.degree. (dil. EtOH); p-HO2CCH2C6H4, Me, H, Ph, 189-90.degree. (dil. EtOH). The following VI are prepd. (R and m.p. given): n, 154-6.degree. (EtOH); o, 95-7.degree. (EtOH); p, 240.degree. (decompn.) (MeSOMe); q, 244.degree. (MeSOMe); a, 272.degree. (MeSOMe); r, 220.degree. (EtOH). 2-(1-Pyrazolyl)-4-hydroxypyrimidines were effective in inhibiting growth of Mycobacterium tuberculosis.

IT **91644-40-5**, Pyrazole-4-carboxylic acid, 1-(2-amino-6-methyl-4-pyrimidinyl)-5-methyl-, ethyl ester **92555-72-1**, Pyrazole-4-carboxylic acid, 1-(2-amino-6-methyl-4-pyrimidinyl)-5-phenyl- **93351-00-9**, Pyrazole-4-carboxylic acid, 5-amino-1-(2-amino-6-methyl-4-pyrimidinyl)-, ethyl ester **93435-99-5**, Pyrazole-4-carboxylic acid, 1-(2-amino-6-methyl-4-pyrimidinyl)-5-phenyl-, ethyl ester **93871-87-5**, Pyrazole-4-carboxylic acid, 1-(2-anilino-6-methyl-4-pyrimidinyl)-5-methyl-, ethyl ester **94069-65-5**, Pyrazole-4-carboxylic acid, 5-amino-1-[2-(benzylamino)-6-methyl-4-pyrimidinyl]-, ethyl ester **94378-89-9**, Pyrazole-4-carboxylic acid, 1-[2-(benzylamino)-6-methyl-4-pyrimidinyl]-5-methyl-, ethyl ester **94711-75-8**, Pyrazole-4-carboxylic acid, 5-amino-1-(2-anilino-6-methyl-4-pyrimidinyl)-, ethyl ester
(prepn. of)

RN 91644-40-5 CAPLUS

CN Pyrazole-4-carboxylic acid, 1-(2-amino-6-methyl-4-pyrimidinyl)-5-methyl-, ethyl ester (7CI) (CA INDEX NAME)



RN 92555-72-1 CAPLUS
CN Pyrazole-4-carboxylic acid, 1-(2-amino-6-methyl-4-pyrimidinyl)-5-phenyl- (7CI) (CA INDEX NAME)



RN 93351-00-9 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 5-amino-1-(2-amino-6-methyl-4-pyrimidinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 93435-99-5 CAPLUS
CN Pyrazole-4-carboxylic acid, 1-(2-amino-6-methyl-4-pyrimidinyl)-5-phenyl-, ethyl ester (7CI) (CA INDEX NAME)



RN 93871-87-5 CAPLUS
CN Pyrazole-4-carboxylic acid, 1-(2-anilino-6-methyl-4-pyrimidinyl)-5-methyl-, ethyl ester (7CI) (CA INDEX NAME)



RN 94069-65-5 CAPLUS
CN Pyrazole-4-carboxylic acid, 5-amino-1-[2-(benzylamino)-6-methyl-4-pyrimidinyl]-, ethyl ester (7CI) (CA INDEX NAME)



RN 94378-89-9 CAPLUS
CN Pyrazole-4-carboxylic acid, 1-[2-(benzylamino)-6-methyl-4-pyrimidinyl]-5-methyl-, ethyl ester (7CI) (CA INDEX NAME)



RN 94711-75-8 CAPLUS
CN Pyrazole-4-carboxylic acid, 5-amino-1-(2-anilino-6-methyl-4-pyrimidinyl)-, ethyl ester (7CI) (CA INDEX NAME)



```
=> d his

     (FILE 'HOME' ENTERED AT 19:01:06 ON 01 JUL 2003)

     FILE 'REGISTRY' ENTERED AT 19:01:10 ON 01 JUL 2003
L1             STRUCTURE UPLOADED
L2               1 S L1 SSS SAM
L3             237 S L1 SSS FUL

     FILE 'CAPLUS' ENTERED AT 19:02:12 ON 01 JUL 2003
L4              20 S L3

     FILE 'CAOLD' ENTERED AT 19:03:00 ON 01 JUL 2003

=> s l3
L5               3 L3

=> d l5 1-3 bib,hitstr
```

L5 ANSWER 1 OF 3 CAOLD COPYRIGHT 2003 ACS
AN CA61:7026d CAOLD
TI 2,6-bis(ethanolamino)pyrimido[5,4-d]pyrimidines
AU Roch, Josef
DT Patent
TI 2,6-bis(ethanolamino)pyrimido[5,4-d]pyrimidines
AU Thomae, Dr. Karl, G.m.b.H.
DT Patent

PATENT NO.	KIND	DATE
DE 1172685		

IT **93435-99-5**
RN 93435-99-5 CAOLD
CN Pyrazole-4-carboxylic acid, 1-(2-amino-6-methyl-4-pyrimidinyl)-5-phenyl-, ethyl ester (7CI) (CA INDEX NAME)



L5 ANSWER 2 OF 3 CAOLD COPYRIGHT 2003 ACS
AN CA61:7025f CAOLD
TI 4-(1-pyrazolyl)pyrimidines
AU Shirakawa, Kenzo; Tsujikawa, T.
PA Takeda Chemical Industries, Ltd.
DT Patent

PATENT NO.	KIND	DATE
JP 64005040		1964

IT **91644-40-5 93351-00-9 93871-87-5 94069-65-5 94378-89-9 94711-75-8**

RN 91644-40-5 CAOLD
CN Pyrazole-4-carboxylic acid, 1-(2-amino-6-methyl-4-pyrimidinyl)-5-methyl-, ethyl ester (7CI) (CA INDEX NAME)



RN 93351-00-9 CAOLD
CN 1H-Pyrazole-4-carboxylic acid, 5-amino-1-(2-amino-6-methyl-4-pyrimidinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 93871-87-5 CAOLD
CN Pyrazole-4-carboxylic acid, 1-(2-anilino-6-methyl-4-pyrimidinyl)-5-methyl-, ethyl ester (7CI) (CA INDEX NAME)



RN 94069-65-5 CAOLD
CN Pyrazole-4-carboxylic acid, 5-amino-1-[2-(benzylamino)-6-methyl-4-pyrimidinyl]-, ethyl ester (7CI) (CA INDEX NAME)



RN 94378-89-9 CAOLD
CN Pyrazole-4-carboxylic acid, 1-[2-(benzylamino)-6-methyl-4-pyrimidinyl]-5-methyl-, ethyl ester (7CI) (CA INDEX NAME)



RN 94711-75-8 CAOLD
CN Pyrazole-4-carboxylic acid, 5-amino-1-(2-anilino-6-methyl-4-pyrimidinyl)-, ethyl ester (7CI) (CA INDEX NAME)



L5 ANSWER 3 OF 3 CAOLD COPYRIGHT 2003 ACS
AN CA60:12009b CAOLD
TI pyrimidine derivs. - (XI) 2-(pyrazolyl)- pyrimidines (1), (XII) 2-[1-pyrazolyl)pyrimidines (2)
AU Shirakawa, Kenzo; Tsujikawa, T.
IT **91644-40-5 92555-72-1 93351-00-9 93435-99-5 93871-87-5 94069-65-5 94378-89-9 94711-75-8**
RN 91644-40-5 CAOLD
CN Pyrazole-4-carboxylic acid, 1-(2-amino-6-methyl-4-pyrimidinyl)-5-methyl-, ethyl ester (7CI) (CA INDEX NAME)



RN 92555-72-1 CAOLD
CN Pyrazole-4-carboxylic acid, 1-(2-amino-6-methyl-4-pyrimidinyl)-5-phenyl- (7CI) (CA INDEX NAME)



RN 93351-00-9 CAOLD
CN 1H-Pyrazole-4-carboxylic acid, 5-amino-1-(2-amino-6-methyl-4-pyrimidinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 93435-99-5 CAOLD
CN Pyrazole-4-carboxylic acid, 1-(2-amino-6-methyl-4-pyrimidinyl)-5-phenyl-, ethyl ester (7CI) (CA INDEX NAME)



RN 93871-87-5 CAOLD
CN Pyrazole-4-carboxylic acid, 1-(2-anilino-6-methyl-4-pyrimidinyl)-5-methyl-, ethyl ester (7CI) (CA INDEX NAME)



RN 94069-65-5 CAOLD
CN Pyrazole-4-carboxylic acid, 5-amino-1-[2-(benzylamino)-6-methyl-4-pyrimidinyl]-, ethyl ester (7CI) (CA INDEX NAME)



RN 94378-89-9 CAOLD
CN Pyrazole-4-carboxylic acid, 1-[2-(benzylamino)-6-methyl-4-pyrimidinyl]-5-methyl-, ethyl ester (7CI) (CA INDEX NAME)



RN 94711-75-8 CAOLD
CN Pyrazole-4-carboxylic acid, 5-amino-1-(2-anilino-6-methyl-4-pyrimidinyl)-, ethyl ester (7CI) (CA INDEX NAME)


PhNH
N
N
N
N
Me
H2N
C—OEt
O

```
=> d his

     (FILE 'HOME' ENTERED AT 19:01:06 ON 01 JUL 2003)

     FILE 'REGISTRY' ENTERED AT 19:01:10 ON 01 JUL 2003
L1                STRUCTURE UPLOADED
L2              1 S L1 SSS SAM
L3            237 S L1 SSS FUL

     FILE 'CAPLUS' ENTERED AT 19:02:12 ON 01 JUL 2003
L4             20 S L3

     FILE 'CAOLD' ENTERED AT 19:03:00 ON 01 JUL 2003
L5              3 S L3

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       8.26     248.16

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00     -13.02

STN INTERNATIONAL LOGOFF AT 19:03:38 ON 01 JUL 2003
```